MX2022014048A - Proceso para la preparacion de sales de compuestos triazolicos. - Google Patents
Proceso para la preparacion de sales de compuestos triazolicos.Info
- Publication number
- MX2022014048A MX2022014048A MX2022014048A MX2022014048A MX2022014048A MX 2022014048 A MX2022014048 A MX 2022014048A MX 2022014048 A MX2022014048 A MX 2022014048A MX 2022014048 A MX2022014048 A MX 2022014048A MX 2022014048 A MX2022014048 A MX 2022014048A
- Authority
- MX
- Mexico
- Prior art keywords
- dilauryl
- glyceryl
- salt
- discloses
- triazole
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- -1 triazole compounds Chemical class 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000012454 non-polar solvent Substances 0.000 abstract 2
- 239000002798 polar solvent Substances 0.000 abstract 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229960004130 itraconazole Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229960001589 posaconazole Drugs 0.000 abstract 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
- 229960004740 voriconazole Drugs 0.000 abstract 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/60—Maleic acid esters; Fumaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención da a conocer un proceso a gran escala para la preparación de compuestos triazólicos, al utilizar solventes polares y no polares. Con mayor particularidad, se refiere a un método de preparación de la sal dilauril gliceril fumarato de posaconazol, voriconazol e itraconazol, respectivamente. El método se comprende de disolver un compuesto triazólico y dilauril gliceril fumarato en un solvente polar adecuado, en un intervalo de temperatura de 30 a 55 °C para la formación de sales, y la sal final se aísla al utilizar un solvente no polar en un intervalo de baja temperatura de 0 a 35 °C. Además da a conocer un método de producción de un tamaño en partículas finas de la sal dilauril gliceril fumarato del triazol, de preferencia en el tamaño que varía de 0.001 micras a 100 micras. También da a conocer un método de elaboración de una preparación farmacéutica deseada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041019951 | 2020-05-12 | ||
| PCT/IB2021/053696 WO2021229359A2 (en) | 2020-05-12 | 2021-05-04 | Process for the preparation salts of triazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014048A true MX2022014048A (es) | 2022-11-30 |
Family
ID=78526475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014048A MX2022014048A (es) | 2020-05-12 | 2021-05-04 | Proceso para la preparacion de sales de compuestos triazolicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230219936A1 (es) |
| EP (1) | EP4149935A4 (es) |
| JP (1) | JP2023525787A (es) |
| KR (1) | KR20230009946A (es) |
| AU (1) | AU2021272730A1 (es) |
| BR (1) | BR112022022795A2 (es) |
| CA (1) | CA3178643A1 (es) |
| IL (1) | IL298010A (es) |
| MX (1) | MX2022014048A (es) |
| WO (1) | WO2021229359A2 (es) |
| ZA (1) | ZA202212697B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL287622B (en) * | 2016-11-28 | 2022-07-01 | Cellix Bio Private Ltd | Preparations and methods for treating fungal infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1372394A1 (en) * | 2001-04-03 | 2004-01-02 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| WO2005118577A1 (en) * | 2004-04-22 | 2005-12-15 | Transform Pharmaceuticals, Inc. | Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| CN1847243A (zh) * | 2005-07-08 | 2006-10-18 | 北京博尔达生物技术开发有限公司 | 一种新的伏立康唑可溶性盐的制备方法及其制剂 |
| WO2009053993A2 (en) * | 2007-10-22 | 2009-04-30 | Lee Pharma Limited | Process for preparation of novel salt of voriconazole oxalate form-c |
| IL287622B (en) * | 2016-11-28 | 2022-07-01 | Cellix Bio Private Ltd | Preparations and methods for treating fungal infections |
-
2021
- 2021-05-04 IL IL298010A patent/IL298010A/en unknown
- 2021-05-04 EP EP21804885.8A patent/EP4149935A4/en not_active Withdrawn
- 2021-05-04 MX MX2022014048A patent/MX2022014048A/es unknown
- 2021-05-04 WO PCT/IB2021/053696 patent/WO2021229359A2/en not_active Ceased
- 2021-05-04 CA CA3178643A patent/CA3178643A1/en active Pending
- 2021-05-04 JP JP2022568513A patent/JP2023525787A/ja active Pending
- 2021-05-04 BR BR112022022795A patent/BR112022022795A2/pt not_active Application Discontinuation
- 2021-05-04 AU AU2021272730A patent/AU2021272730A1/en not_active Abandoned
- 2021-05-04 KR KR1020227043151A patent/KR20230009946A/ko not_active Withdrawn
- 2021-05-04 US US17/925,288 patent/US20230219936A1/en active Pending
-
2022
- 2022-11-22 ZA ZA2022/12697A patent/ZA202212697B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL298010A (en) | 2023-01-01 |
| EP4149935A4 (en) | 2024-06-05 |
| WO2021229359A2 (en) | 2021-11-18 |
| WO2021229359A3 (en) | 2022-01-06 |
| ZA202212697B (en) | 2023-04-26 |
| JP2023525787A (ja) | 2023-06-19 |
| US20230219936A1 (en) | 2023-07-13 |
| BR112022022795A2 (pt) | 2022-12-13 |
| KR20230009946A (ko) | 2023-01-17 |
| CA3178643A1 (en) | 2021-11-18 |
| EP4149935A2 (en) | 2023-03-22 |
| AU2021272730A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60000003T2 (de) | Paroxetinmethansulfonat | |
| JP2019104760A (ja) | ベンズイミダゾール誘導体の新規結晶形及びその製造方法 | |
| EA201991055A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛ[1,5-a]ПИРИМИДИНОВ И ИХ СОЛЕЙ | |
| RU2017115925A (ru) | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе | |
| AU2014259029B2 (en) | Polymorphic forms of nilotinib hydrochloride | |
| DE602004012559T2 (de) | 4-SUBSTITUIERTE DERIVATE VON PYRAZOLOi3,4-D PYRIMIDIN UND DEREN VERWENDUNGEN | |
| EP3283491A1 (en) | New forms of ixazomib citrate | |
| MX2022014048A (es) | Proceso para la preparacion de sales de compuestos triazolicos. | |
| AU2010270202B2 (en) | Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene | |
| JP2020510018A (ja) | 結晶性医薬品の製造 | |
| SG177576A1 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
| JP6887980B2 (ja) | 薬学的に活性な化合物の固体形態 | |
| JP2020508979A (ja) | ３−ｚ−［１−（４−（ｎ−（（４−メチル−ピペラジン−１−イル）−メチルカルボニル）−ｎ−メチル−アミノ）−フェニルアミノ）−１−フェニル−メチレン］−６−メトキシカルボニル−２−インドリノンの結晶形 | |
| WO2016058081A1 (en) | Solid forms of nilotinib hydrochloride | |
| JP2024511296A (ja) | ４ｈ－ピラン－４オンの構造を有するｃｙｐ１１ａ１阻害薬の固体形態 | |
| CN108368096B (zh) | 用于获得坎格列净半水合物晶体的结晶程序 | |
| JP7340534B2 (ja) | トレプロスチニルジエタノールアミン塩の多形形態ｂを製造するための方法 | |
| WO2017211788A1 (en) | Non-crystalline form of palbociclib | |
| CN116113628A (zh) | 一种含cdk4/6抑制剂的药物组合物 | |
| JP2021529803A (ja) | ５−メチル−（６ｓ）−テトラヒドロ葉酸及びアミノ酸エチルエステルの結晶塩 | |
| WO2014174529A2 (en) | Polymorphs of avanafil | |
| JP2026040818A (ja) | 安定なアジルサルタン微細結晶の製造方法 | |
| WO2016127962A1 (en) | An amorphous solid form of suvorexant with sulphuric acid | |
| NZ764730A (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| DE20022645U1 (de) | Paroxetinmethansulfonat |